The hormonal patch producer, backed by Kaiser Permanente, floated below the $69m it had targeted.
US-based women’s healthcare technology developer Agile Therapeutics, which counts managed care consortium Kaiser Permanente among its investors, has raised about $55m in its initial public offering.
The company had hoped to raise up to $69m but priced almost 9.2 million shares at $6 each, before any extra demand is accounted for. Investment banks RBC Capital Markets and William Blair ran the IPO.
Kaiser Permanente Ventures, the corporate venturing arm of Kaiser Permanente, had been an investor since Agile’s $45m series…
